Description

Arixtra (fondaparinux natrium) 2.5 mg/0.5 ml. №10

Ingredients

Active ingredient: Fondaparinux natrium
Inactive ingredients: Sodium chloride, water for injection

Dosage

Dosage: The usual dose of Arixtra is 2.5 mg administered subcutaneously once daily. Dosage adjustments may be necessary based on individual patient characteristics.

Indications

Indications: Arixtra is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture surgery.

Contraindications

Contraindications: Arixtra is contraindicated in patients with active major bleeding, bacterial endocarditis, or severe renal impairment.

Directions

Administration: Arixtra should be administered subcutaneously. It is important to rotate the injection sites and avoid intramuscular administration.

Scientific Evidence

Arixtra (fondaparinux natrium) has been extensively studied in clinical trials for its efficacy in preventing thromboembolic events. Research by Turpie AG et al. demonstrated that fondaparinux was superior to enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery.

Additional Information

It is essential to monitor for signs of bleeding during Arixtra therapy, especially in patients with a high risk of bleeding. Arixtra should be used with caution in patients with renal impairment as dosage adjustments may be necessary.

Pharmacological Effects: Fondaparinux natrium, the active ingredient in Arixtra, is a synthetic pentasaccharide that selectively inhibits factor Xa. By targeting factor Xa, Arixtra effectively prevents the formation of blood clots.

Clinical Trials: Clinical trials have shown that Arixtra is effective in preventing deep vein thrombosis and pulmonary embolism in patients undergoing orthopedic surgery. In a study by Eriksson BI et al., Arixtra demonstrated a significant reduction in the incidence of venous thromboembolism compared to placebo.